Erasca, Inc. Files 8-K: Material Agreement & Equity Sales
Ticker: ERAS · Form: 8-K · Filed: Mar 28, 2024 · CIK: 1761918
Sentiment: neutral
Topics: material-agreement, equity-sale, filing
TL;DR
Erasca 8-K: Material agreement signed, equity sold, financial docs filed.
AI Summary
On March 27, 2024, Erasca, Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities and provided a Regulation FD disclosure. This filing includes financial statements and exhibits related to these events.
Why It Matters
This 8-K filing indicates significant corporate activity for Erasca, Inc., including a new material agreement and equity transactions, which could impact its financial standing and strategic direction.
Risk Assessment
Risk Level: medium — The filing details a material definitive agreement and unregistered equity sales, which can introduce financial and operational risks.
Key Numbers
- 001-40602 — SEC File Number (Identifies the specific filing for Erasca, Inc.)
- 83-1217027 — IRS Employer Identification No. (Tax identification for Erasca, Inc.)
Key Players & Entities
- Erasca, Inc. (company) — Registrant
- March 27, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- San Diego, California (location) — Principal Executive Offices
FAQ
What is the nature of the material definitive agreement entered into by Erasca, Inc. on March 27, 2024?
The filing indicates Erasca, Inc. entered into a material definitive agreement on March 27, 2024, but the specific details of this agreement are not provided in the summary text.
What type of equity securities were sold in the unregistered sales reported by Erasca, Inc.?
The filing mentions unregistered sales of equity securities, but the specific type and details of these securities are not elaborated in the provided text.
What is the primary business of Erasca, Inc. according to the filing?
Erasca, Inc. is classified under the Standard Industrial Classification code 2834, which pertains to Pharmaceutical Preparations.
Where are Erasca, Inc.'s principal executive offices located?
Erasca, Inc.'s principal executive offices are located at 3115 Merryfield Row Suite 300, San Diego, California, 92121.
What is the significance of the 'Regulation FD Disclosure' mentioned in the filing?
A Regulation FD Disclosure indicates that the company is providing information to the public that could be considered material non-public information, ensuring fair disclosure to all investors.
Filing Stats: 1,544 words · 6 min read · ~5 pages · Grade level 14.6 · Accepted 2024-03-28 16:14:07
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share ERAS Nasdaq Glo
- $2.06 — are (the "Common Stock"), at a price of $2.06 per Share. The aggregate gross proceeds
- $45 m — cement are expected to be approximately $45 million, before deducting offering fees a
Filing Documents
- d808774d8k.htm (8-K) — 35KB
- d808774dex101.htm (EX-10.1) — 207KB
- d808774dex991.htm (EX-99.1) — 9KB
- 0001193125-24-080630.txt ( ) — 443KB
- eras-20240327.xsd (EX-101.SCH) — 3KB
- eras-20240327_lab.xml (EX-101.LAB) — 18KB
- eras-20240327_pre.xml (EX-101.PRE) — 11KB
- d808774d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 10.1 Stock Purchase Agreement, dated March 27, 2024, by and between Erasca, Inc. and each of the purchasers party thereto 99.1 Press Release issued on March 27, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
Forward-Looking Statements
Forward-Looking Statements Erasca cautions you that statements contained in this report regarding matters that are not historical facts are forward-looking statements. The forward-looking statements are based on our current beliefs and expectations and include, but are not limited to, statements regarding: the timing, size and expectation of the closing of the Private Placement; expectations regarding market conditions, the satisfaction of customary closing conditions related to the Private Placement, and the anticipated use of proceeds therefrom; the anticipated filing of a registration statement to cover the resale of Shares; and the Company's expectation that its current cash, cash equivalents, and marketable securities will fund its operations into the second half of 2026. The inclusion of forward-looking statements should not be regarded as a representation by the Company that any of these plans will be achieved. Actual results may differ from those set forth in this report on Form 8-K due to the risks and uncertainties inherent in the Company's business and beyond its control, including, without limitation: the risks and uncertainties associated with market conditions and the satisfaction of customary closing conditions related to the Private Placement; the ability to fund the Company's operating plans with its cash, cash equivalents, and marketable securities, including the anticipated proceeds from the Private Placement; and other risks described in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, and in any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisi
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Erasca, Inc. Date: March 28, 2024 By: /s/ Ebun Garner Ebun Garner, General Counsel